NHI.no
Annonse
Informasjon

Irritabel tarm syndrom

Irritabel tarm syndrom er en forstyrrelse i tarmens funksjon kjennetegnet av magesmerter, ubehag, oppblåsthet og forstyrret avføringsmønster med diaré og/eller forstoppelse. Symptomene lindres ved avgang av luft og avføring.

Illustrasjonsfoto

Sist oppdatert:

24. jan. 2023

Vil du vite mer

Dette dokumentet er basert på det profesjonelle dokumentet Irritabel tarm-syndrom . Referanselisten for dette dokumentet vises nedenfor

  1. Snyder N. Irritable bowel syndrome. BMJ Best Practice, last reviewed 22 Nov 2021. bestpractice.bmj.com
  2. Ford AC, Lacy BE, Talley NJ. Irritable bowel syndrome. N Engl J Med. 2017 Jun 29;376(26):2566-2578. PMID: 28657875.
  3. Vandvik, P. O. and Lydersen S, Farup PG. Prevalence, impact and comorbidity of IBS in Norway. Scand J Gastroenterol 2006; 41: 650-6. PubMed
  4. Johansen SG, Ness-Jensen E. The changes in prevalence and risk of irritable bowel syndrome over time in a population-based cohort, the HUNT study, Norway. Scand J Gastroenterol. 2022 Feb 4:1-7. Epub ahead of print. PMID: 35119352. PubMed
  5. Agrawal A, Houghton LA, Reilly B, et al. Bloating and distension in irritable bowel syndrome: the role of gastrointestinal transit. Am J Gastroenterol 2009; 104:1998. PubMed
  6. Lehrer JK. Irritable bowel syndrome. Medscape, last updated Apr 04, 2017. emedicine.medscape.com
  7. Klem F, Wadhwa A, Prokop LJ, et al. Prevalence, Risk Factors, and Outcomes of Irritable Bowel Syndrome After Infectious Enteritis: A Systematic Review and Meta-analysis. Gastroenterology. 2017;152(5):1042-1054.e1. PMID: 28069350 PubMed
  8. Ford AC, Sperber AD, Corsetti M, Camilleri M. Irritable bowel syndrome. Lancet. 2020;396(10263):1675-1688. PMID: 33049223 PubMed
  9. Carroccio A, Mansueto P, Iacono G, et al. Non-celiac wheat sensitivity diagnosed by double-blind placebo-controlled challenge: exploring a new clinical entity. Am J Gastroenterol 2012; 107: 1898-906. PubMed
  10. Ford AC, Vandvik PO. Irritable bowel syndrome: dietary interventions. Systematic review 410. BMJ Clinical Evidence 2015.
  11. Rej A, Sanders DS. Gluten-free diet and its ‘cousins’ in irritable bowel syndrome. Nutrients. 2018 Nov; 10(11): 1727. www.ncbi.nlm.nih.gov
  12. Gibson PR, Shepherd SJ. Evidence-based dietary management of functional gastrointestinal symptoms: The FODMAP approach. Journal of Gastroenterology and Hepatology 2010; 25: 252-8. PubMed
  13. Melchior C, Gourcerol G, Dechelotte P, et al. Symptomatic fructose malasorption in irritable bowel syndrome: A prospective study. Un Eur Gastroenterol J 2014; 2: 131-7. doi: 10.1177/2050640614521124 DOI
  14. Benardout M, Le Gresley A, ElShaer A, Wren SP. Fructose malabsorption: causes, diagnosis and treatment. Br J Nutr. 2022;127(4):481-489. PubMed
  15. Begtrup LM, Engsbro AL, Kjeldsen J, et al. A positive diagnostic strategy is noninferior to a strategy of exclusion for patients with irritable bowel syndrome. Clin Gastroenterol Hepatol 2013;11:956-62.e1. PMID: 23357491.
  16. Vasant DH, Paine PA, Black CJ, et al. British Society of Gastroenterology guidelines on the management of irritable bowel syndrome. Gut 2021; 70: 1214-40. PMID: 33903147 PubMed
  17. Schmulson MJ, Drossman DA. What is new in Rome IV. J Neurogastroenterol Motil 2017; 23 (2): 151-63.
  18. Cristofori F, Fontana C, Magista A, et al. Increased prevalence of celiac disease among pediatric patients with irritable bowel syndrome. A 6-year prospective chort study. JAMA Pediatr 2014. doi:10.1001/jamapediatrics.2013.4984 DOI
  19. Carroccio A, Mansueto P, Iacono G, et al. Non-celiac wheat sensitivity diagnosed by double-blind placebo-controlled challenge: Exploring a new clinical entity. Am J Gastroenterol, 2012. doi:10.1038/ajg.2012.236 DOI
  20. Rostom A, Dubé C, Cranney A, et al. The diagnostic accuracy of serologic tests for celiac disease: a systematic review. Gastroenterology 2005; 128 (4 Suppl 1): 38-46.
  21. Irvine AJ, Chey WD, Ford AC. Screening for Celiac Disease in Irritable Bowel Syndrome: An Updated Systematic Review and Meta-analysis. Am J Gastroenterol. 2017;112(1):65-76. PubMed
  22. Waugh N, Cummins E, Royle P, et al. Review: Calprotectin testing differentiates inflammatory bowel disease from the irritiable bowel syndrome. Ann Intern Med 2014; 160: JC13. doi:10.7326/0003-4819-160-8-201404150-02013 DOI
  23. Menees SB, Powell C, Kurlander J, et al. A Meta-Analysis of the Utility of C-Reactive Protein, Erythrocyte Sedimentation Rate, Fecal Calprotectin, and Fecal Lactoferrin to Exclude Inflammatory Bowel Disease in Adults With IBS. Am J Gastroenterol 2015; 110: 444-54. doi:10.1038/ajg.2015.6 DOI
  24. Maagaard L, Ankersen DV, Vegh Z, et al. Follow-up of patients with functional bowel symptoms treated with a low FODMAP diet. World J Gastroenterol 2016; 22: 4009-19. pmid:27099444 PubMed
  25. Black CJ, Staudacher HM, Ford AC Efficacy of a low FODMAP diet in irritable bowel syndrome: systematic review and network meta-analysis. Gut. 2021. PMID: 34376515 PubMed
  26. NICE guideline. Irritable bowel syndrome in adults: diagnosis and management of irritable bowel syndrome in primary care. NICE guideline CG61, 2015.
  27. Ford AC, Moayyedi P. Meta-analysis: factors affecting placebo response rate in the irritable bowel syndrome. Aliment Pharmacol Ther 2010;32:144-158. PubMed
  28. Nurko S, Saps M, Kossovsky J, et al. Effect of Open-label Placebo on Children and Adolescents With Functional Abdominal Pain or Irritable Bowel Syndrome A Randomized Clinical Trial. JAMA Pediatr 2022. doi:10.1001/jamapediatrics.2021.5750 DOI
  29. El-Salhy M, Hatlebakk JG, Gilja OH et al. Efficacy of faecal microbiota transplantation for patients with irritable bowel syndrome in a randomised, double-blind, placebo-controlled study. Gut 2019. Epub ahead of print. pmid:31852769 PubMed
  30. Everitt HA, Landau S, O'Reilly G, et al. Assessing telephone-delivered cognitive–behavioural therapy (CBT) and web-delivered CBT versus treatment as usual in irritable bowel syndrome (ACTIB): a multicentre randomised trial. Gut, published online first: 10 April 2019. gut.bmj.com
  31. Robinson A, Lee V, Kennedy A, et al. A randomised controlled trial of self-help interventions in patients with a primary care diagnosis of irritable bowel syndrome. Gut 2006; 55: 643-8. Gut
  32. Staudacher HM1, Whelan K, et.al. Comparison of symptom response following advice for a diet low in fermentable carbohydrates (FODMAPs) versus standard dietary advice in patients with irritable bowel syndrome. J Hum Nutr Diet, Oct 2011; 24(5): 487-95.
  33. Halmos E, Power V, et.al. A diet low in FODMAPs reduces symptoms of irritable bowel syndrome. Gastroenterology 2014; 146: 67-75. Gastroenterology
  34. Dionne J, Ford AC, Yuhong Y et al. A Systematic Review and Meta-Analysis Evaluating the Efficacy of a Gluten-Free Diet and a Low FODMAPs Diet in Treating Symptoms of Irritable Bowel Syndrome. Am J Gastroenterol 2018. pmid:30046155 PubMed
  35. Carbone F, Van den Houte K, Besard L et al. DOMINO Study Collaborators; Domino Study Collaborators. Diet or medication in primary care patients with IBS: the DOMINO study - a randomised trial supported by the Belgian Health Care Knowledge Centre (KCE Trials Programme) and the Rome Foundation Research Institute. Gut. 2022 Apr 28:gutjnl-2021-325821. Epub ahead of print. PMID: 35483886 PubMed
  36. Ford AC, Moayyedi P, Lacy BE, et al. American College of Gastroenterology monograph on the management of irritable bowel syndrome and chronic idiopathic constipation. Am J Gastroenterol 2014;109:Suppl 1:S2-S26. PMID: 25091148. PubMed
  37. Moayyedi P, Quigley EM, Lacy BE, et al. The effect of fiber supplementation on irritable bowel syndrome: a systematic review and meta-analysis. Am J Gastroenterol. 2014 Sep;109(9):1367-74. PMID: 25070054 PubMed
  38. Bijkerk CJ, de Wit NJ, Muris JWM, et al. Soluble og insoluble fibre in irritable bowel syndrome in primary care? Randomised placebo controlled trial. BMJ 2009; 339: b3154. BMJ (DOI)
  39. Moayyedi P, Ford AC, Talley NJ, et al.The efficacy of probiotics in the treatment of irritable bowel syndrome: a systematic review. Gut 2010; 59: 325-32. Gut
  40. Rao S, Lembo AJ, Shiff SJ, et al. A 12-week, randomized, controlled trial with a 4-week randomized withdrawal period to evaluate the efficacy and safety of linaclotide in irritable bowel syndrome with constipation. Am J Gastroenterol 2012 Sep 18. pmid:22986440 PubMed
  41. Shah ED, Kim HM, Schoenfeld P. Efficacy and Tolerability of Guanylate Cyclase-C Agonists for Irritable Bowel Syndrome with Constipation and Chronic Idiopathic Constipation: A Systematic Review and Meta-Analysis. Am J Gastroenterol. 2018. PMID: 29380823 PubMed
  42. Ford AC, Quigley EM, Lacy BE, et al. Efficacy of prebiotics, probiotics, and synbiotics in irritable bowel syndrome and chronic idiopathic constipation: Systematic review and meta-analysis. Am J Gastroenterol 2014 Oct; 109:1547 doi:10.1038/ajg.2014.202 DOI
  43. Layer P, Stanghellini V. Linaclotide for the management of irritable bowel syndrome with constipation. Aliment Pharmacol Ther 2014; 39: 371-84. PubMed
  44. Chang L, Sultan S, Lembo A, et al. AGA Clinical Practice Guideline on the Pharmacological Management of Irritable Bowel Syndrome With Constipation. Gastroenterology 2022; 163: 118-136. pmid:35738724 PubMed
  45. Chey WD, Lembo AJ, Lavins BJ, et al. Linaclotide for irritable bowel syndrome with constipation: a 26-week, randomized, double-blind, placebo-controlled trial to evaluate efficacy and safety. Am J Gastroenterol 2012 Sep 18. pmid:22986437 PubMed
  46. Brenner DM, Fogel R, Dorn SD, et al. Efficacy, safety, and tolerability of plecanatide in patients with irritable bowel syndrome with constipation: results of two phase 3 randomized clinical trials. Am J Gastroenterol 2018. pmid:29545635 PubMed
  47. Shin A, Camilleri M, Kolar G, et al. Systematic review with meta-analysis: highly selective 5-HT4 agonists (prucalopride, velusetrag or naronapride) in chronic constipation. Aliment Pharmacol Ther 2014; 39: 239-53. pmid: 24308797 PubMed
  48. Chey WD, Lembo AJ, Rosenbaum DP Efficacy of Tenapanor in Treating Patients With Irritable Bowel Syndrome With Constipation: A 12-Week, Placebo-Controlled Phase 3 Trial (T3MPO-1). Am J Gastroenterol. 2020. PMID: 31934897 PubMed
  49. Ruepert L, Quartero AO, de Wit NJ, van der Heijden GJ, Rubin G, Muris JWM. Bulking agents, antispasmodics and antidepressants for the treatment of irritable bowel syndrome. Cochrane Database of Systematic Reviews 2011, Issue 8. Art. No.: CD003460. DOI: 10.1002/14651858.CD003460.pub3. Accessed 15 July 2022. The Cochrane Library
  50. Lembo A, Sultan S, Chang L, et al. AGA Clinical Practice Guideline on the Pharmacological Management of Irritable Bowel Syndrome With Diarrhea. Gastroenterology 2022; 163: 137-151. pmid:35738725 PubMed
  51. Fukudo S, Kinoshita Y, Okumura T, et al. Ramosetron reduces symptoms of irritable bowel syndrome with diarrhea and improves quality of life in women. Gastroenterology. 2016: 150: 358-66. PMID: 26551550 PubMed
  52. Ferreira GE, Abdel-Shaheed C, Underwood M, et al. Efficacy, safety, and tolerability of antidepressants for pain in adults: overview of systematic reviews. BMJ 2023; 380: e072415. pmid:36725015 PubMed
  53. Ford AC, Wright-Hughes A, Alderson SL, et al. Amitriptyline at Low-Dose and Titrated for Irritable Bowel Syndrome as Second-Line Treatment in primary care (ATLANTIS): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet 2023; 402: 1773-1775. pmid:37858323 PubMed
  54. Khanna R, MacDonald JK, Levesque BG. Peppermint oil for the treatment of irritable bowel syndrome: a systematic review and meta-analysis. J Clin Gastroenterol 2014; 48: 505-12. pmid:24100754 PubMed
  55. Nee J, Ballou S, Kelley JM, et al. Peppermint oil treatment for irritable bowel syndrome: A randomized placebo-controlled trial. Am J Gastroenterol 2021. PMID: 34319275 PubMed
  56. Statens Legemiddelverk (SLV). Nye anbefalinger ved bruk av metoklopramid. Juli 2013.
  57. Liu JP, Yang M, Liu Y, Wei ML, Grimsgaard S. Herbal medicines for treatment of irritable bowel syndrome. Cochrane Database of Systematic Reviews 2006, Issue 1. Art. No.: CD004116. DOI: 10.1002/14651858.CD004116.pub2. DOI
  58. Garsed K, Chernova J, Hastings M, et al. A randomised trial of ondansetron for the treatment of irritable bowel syndrome with diarrhoea. Gut 2013 Dec 12.
  59. Chen KH, Zeng BY, Zeng BS, et al. The efficacy of exogenous melatonin supplement in ameliorating irritable bowel syndrome severity: A meta-analysis of randomized controlled trials published online ahead of print, 2022 Oct 15. J Formos Med Assoc. 2022;S0929-6646(22)00385-0. PMID: 36257872 PubMed
  60. Tazzyman S, Richards N, Trueman AR, et al. Vitamin D associates with improved quality of life in participants with irritable bowel syndrome: outcomes from a pilot trial. BMJ Open Gastro 2015; 2:e000052 . doi:10.1136/bmjgast-2015-000052 DOI
  61. Kaptchuk TJ, Kelley JM, Conboy LA, et al. Components of placebo effect: randomised controlled trial in patients with irritable bowel syndrome. BMJ 2008; 336: 999-1003. PubMed
  62. Ford AC, Talley NJ, Schoenfeld PS, et al. Efficacy of antidepressants and psychological therapies in irritable bowel syndrome: systematic review and meta-analysis. Gut 2009; 58: 367-78.
  63. Halkjær SI, Christensen AH, Lo BZS, et al Faecal microbiota transplantation alters gut microbiota in patients with irritable bowel syndrome: results from a randomised, double-blind placebo-controlled study Gut Published Online First: 06 July 2018.
  64. Canavan C, West J, Card T. The economic impact of the irritable bowel syndrome. Aliment Pharmacol Ther 2014;40:1023-1034. PubMed
  65. Biekiesiekierski JR, Newbham ED, Irving PM, et al. Gluten causes gastrointetinal symptoms in subjects without celiac disease: a double-blind randomized placebo-contgrolled trial. Am J Gastroenterol 2011; 106: 508-14. PubMed
  66. Biesiekierski JR, Peters SL, Newnham ED, et al. No effects of gluten in patients with self-reported non-celilac gluten sensitivity after dietary reduction of fermentable, poorly absorbed, short-chain carbohydrates. Gastroeneterology 2013; 145: 320-8. PubMed
Annonse
Annonse